Bavarian Nordic stock slides on Moderna mpox vaccine study [Seeking Alpha]
Emergent BioSolutions Inc. (EBS)
Last emergent biosolutions inc. earnings: 4/30 04:08 pm
Check Earnings Report
US:NYSE Investor Relations:
investors.emergentbiosolutions.com
Company Research
Source: Seeking Alpha
vaccine being developed by Moderna ( NASDAQ: MRNA ) appeared to be more effective in preventing severe disease than Bavarian's mpox vaccine Jynneos. The study, which was published online in the scientific journal Cell , evaluated Moderna's mpox vaccine candidate mRNA-1769 and Jynneos in non-human primates. Results showed that while both vaccines were able to prevent death from the disease, primates that were given mRNA-1769 developed fewer lesions and other serious symptoms. Demand for vaccines that can protect against mpox, also known as monkeypox, has dramatically increased in recent weeks due to a prolonged outbreak in Africa. Other companies working on vaccines or treatments for the disease include Emergent BioSolutions ( EBS ), Chimerix ( CMRX ), Aspen Pharmacare ( OTCPK:APNHF ), GeoVax Labs ( GOVX ), SIGA Technologies ( SIGA ) and Tonix Pharmaceuticals ( TNXP Companies making tests for the disease include Co-Diagnostics ( CODX ), Roche ( OTCQX:RHHBY OTCQX:RHHBF ), Abbott L
Show less
Read more
Impact Snapshot
Event Time:
EBS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EBS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EBS alerts
High impacting Emergent BioSolutions Inc. news events
Weekly update
A roundup of the hottest topics
EBS
News
- Emergent BioSolutions Inc. (NYSE: EBS) had its "buy" rating re-affirmed by analysts at Rodman & Renshaw. They now have a $16.00 price target on the stock.MarketBeat
- Emergent BioSolutions Announces Agreement to Settle Securities Class Action Litigation [Yahoo! Finance]Yahoo! Finance
- Emergent BioSolutions Announces Agreement to Settle Securities Class Action LitigationGlobeNewswire
- Emergent BioSolutions Awarded Research and Development Option valued at $41.9 Million for continued Advanced Development and Procurement of Ebanga™ Treatment for EbolaGlobeNewswire
- Amid Steep Rise In Mpox Cases, Vaccination Drive In Africa Becomes More Urgent [Forbes]Forbes
EBS
Earnings
- 8/6/24 - Miss
EBS
Sec Filings
- 9/17/24 - Form 8-K
- 9/10/24 - Form SC
- 9/3/24 - Form 8-K
- EBS's page on the SEC website